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Post-PET ultrasound improves specificity
of 18F-FDG-PET for recurrent
differentiated thyroid cancer while
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Jan Erik Varhaug4,8 and Michael Brauckhoff4,8,*
Abstract
Background: Positron emission tomography (PET) using fluor-18-deoxyglucose (18F-FDG) with or without computed
tomography (CT) is generally accepted as the most sensitive imaging modality for diagnosing recurrent differentiated
thyroid cancer (DTC) in patients with negative whole body scintigraphy with iodine-131 (I-131).
Purpose: To assess the potential incremental value of ultrasound (US) over 18F-FDG-PET-CT.
Material and Methods: Fifty-one consecutive patients with suspected recurrent DTC were prospectively evaluated
using the following multimodal imaging protocol: (i) US before PET (pre-US) with or without fine needle biopsy (FNB) of
suspicious lesions; (ii) single photon emission computed tomography (3 GBq I-131) with co-registered CT (SPECT-CT);
(iii) 18F-FDG-PET with co-registered contrast-enhanced CT of the neck; (iv) US in correlation with the other imaging
modalities (post-US). Postoperative histology, FNB, and long-term follow-up (median, 2.8 years) were taken as com-
posite gold standard.
Results: Fifty-eight malignant lesions were identified in 34 patients. Forty lesions were located in the neck or upper
mediastinum. On receiver operating characteristics (ROC) analysis, 18F-FDG-PET had a limited lesion-based specificity
of 59% at a set sensitivity of 90%. Pre-US had poor sensitivity and specificity of 52% and 53%, respectively, increasing to
85% and 94% on post-US, with knowledge of the PET/CT findings (P< 0.05 vs. PET and pre-US). Multimodal imaging
changed therapy in 15 out of 51 patients (30%).
Conclusion: In patients with suspected recurrent DTC, supplemental targeted US in addition to 18F-FDG-PET-CT
increases specificity while maintainin sensitivity, as non-malignant FDG uptake in cervical lesions can be confirmed.
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Introduction
Diﬀerentiated thyroid cancer (DTC), the most common
malignant endocrine tumor, generally has a favorable
prognosis (1). Some patients, however, experience
adverse outcomes despite improvements in preopera-
tive imaging and surgical techniques (2,3).
In most patients with recurrent disease after previous
total thyroidectomy with or without subsequent abla-
tive radioiodine therapy (RIT), serum human thyro-
globulin (hTg) will be detectable as a tumor marker.
Conventional imaging including cervical ultrasound
(US) and computed tomography (CT) is negative in
many cases. Additional tumor lesions may be detected
by iodine-131 (I-131) scintigraphy, particularly after
application of a therapeutic activity of I-131 (4). In
selected patients, I-131 therapy may be curative (5).
In many patients, however, tumor lesions cease to
take up relevant amounts of iodine. In a seminal
paper in 1996, Feine showed that positron emission
tomography (PET) with ﬂuor-18-deoxy-glucose
(FDG) demonstrated thyroid cancer lesions undetect-
able by I-131-scintigraphy (6). Highly diﬀerentiated
thyroid cancer cells exhibit iodine uptake due to the
expression of sodium-iodide symporter (NIS) but
most often no signiﬁcant glucose uptake, while less dif-
ferentiated cells that ceased to express NIS upregulate
glucose and FDG uptake (7–9). 18F-FDG-PET has
therefore become a mainstay in the diagnosis of recur-
rent thyroid cancer, in particular in patients with
elevated serum hTg and negative I-131 scintigraphy
(10–14).
While US is the undisputed ﬁrst choice in the routine
evaluation and follow-up of thyroid cancer patients
(10–12,15,16), its role relative to 18F-FDG-PET is
less well established. We set out to determine the incre-
mental diagnostic value of targeted cervical US
performed after hybrid radionuclide imaging (FDG-
PET-CT and I-131 single photon emission computed
tomographyþCT¼ SPECT-CT) (17) in a prospective
cohort of 50 consecutive patients against composite
gold standard based on histology, cytology, imaging,
and clinical follow-up.
Material and Methods
Patient cohort. Between June 2009 and January 2012, 51
consecutive patients with suspected recurrent or pro-
gressive DTC after previous ablative therapy including
total thyroidectomy (TT) and radioiodine ablation
were prospectively included. Indications for multi-
modal imaging were (one indication per patient): sus-
picious US lesion(s) in 16 patients (31%) (including ﬁve
already conﬁrmed by US-guided ﬁne needle biopsy
[FNB] 10%); increasing/unexplained hTg in 20 patients
(39%); restaging of known metastatic disease in ﬁve
patients (10%); positive TgAB in two patients (4%);
and other indications in eight patients (16%).
Imaging protocol. The multimodal imaging protocol com-
prising US, I-131-SPECT-CT, 18F-FDG-PET, and
US-guided FNB is outlined in Table 1. US was per-
formed by a single experienced operator (MBi) with
10 and 13 MHz linear probes on a Hitachi EUB
5500, and – from February 2011 – a Hitachi Preirus
(Hitachi Medical Corp., Akihabara, Japan). FNB was
performed by the same operator using a modiﬁcation of
Zajdela’s capillary sampling technique (18). Under US
guidance, 0.4 88mm spinal needles (Braun Spinocan;
B. Braun AG, Melsungen, Germany) were advanced to
the border of the lesion. The stylus was then withdrawn
by an assistant and the needle moved inside the lesion.
Sampled material was smeared on glass slides. Air-
dried specimens were stained with Giemsa and ethanol
ﬁxed specimens with Papanicolaou stain. Three or four
FNBs were performed for each lesion. From February
2011, washout from the biopsy needles rinsed with
0.5mL 0.9% sodium chloride solution was additionally
analyzed for hTg and TgAB using the same assays as
for serum samples (19). Post-PET US was performed
for supplementary biopsy or when multimodal imaging
showed extra lesions that had not been diagnosed on
the pre-PET US examination.
I-131-SPECT-CT was performed on a Siemens
Symbia T6 (Siemens Healthcare, Erlangen, Germany)
with high-energy collimators. After a whole body
planar scan, SPECT of the neck and upper mediasti-
num was taken (2 32 projections @ 20 s) with a co-
registered low-dose CT (130 kV, eﬀective tube current
15 mAs).
18F-FDG-PET was performed on a Siemens
Biograph 40 (Siemens Healthcare) after an overnight
fast. Approximately 60min after injection of approxi-
mately 370MBq 18F-FDG, a whole-body PET was
acquired from the skull to the thighs at 3min per bed
position after an initial low-dose CT (120 kV, 50 mAs)
Table 1. Imaging protocol.
Day Procedure(s)
1 Ultrasound, TSH, hTg, hTg-AB
rhTSH i.m.
2 rhTSH i.m.
3 Oral I-131 (3 GBq)
6 I-131 SPECT-CT
7 18F-FDG-PET with dedicated CECT/PET of the neck
US (if new findings on PET-CT), FNB of 1 index lesion
CECT, contrast-enhanced CT (alternatively diagnostic CTwithout intra-
venous contrast in patients with therapeutically relevant I-131 uptake).
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(20). A dedicated PET-CT of the neck and upper medi-
astinum was then performed with the arms down at
6min per bed with a co-registered contrast-enhanced
CT (CECT; 120mV, 240mAs; 2mm slices, ﬁeld of
view 240mm) acquired 50 s after intravenous injection
of 100mL iomeprol (350mg iodine/mL; Bracco
Imaging Scandinavia, AB, Gothenburg, Sweden).
For stimulation with thyroid stimulating hormone
(TSH), patients either received intramuscular injections
of 0.9mg recombinant human TSH (rhTSH,
Thyrogen; Genzyme Corp., Cambridge, MA, USA)
on two successive days, or thyroid hormone was with-
drawn for 4 weeks.
Image processing and analysis. All image data including
US were digitally archived in the department’s Picture
Archiving and Communication System (PACS) (Agfa
Impax 6, Agfa Healthcare BV, Antwerp, Belgium).
US lesions were classiﬁed according to current consen-
sus criteria (21). CTs were read on PACS workstations
using calibrated screens. Nuclear medicine data were
processed with Segami Oasis (v. 1.9.3; Segami
Corporation, Columbia, MD, USA). Maximum
SUV (SUVmax) in PET images was determined by
placing spherical volumes of interest (VOI) around
each focus, preferentially in the dedicated cervical
acquisition. In case of neighboring hot lesions,
custom VOIs were drawn. Lesions were classiﬁed as
FDG-positive when the SUV was 2.5 or when a
focus was clearly discernible against the background
(22,23). I-131 uptake was assessed using a 5-point
qualitative scale (less than background, background,
faint, warm, hot).
Clinical chemistry. Serum thyroglobulin (hTg) and anti-
thyroglobulin antibodies (TgAB) were analyzed by
immunometric assays (Immulite 2000) from
Siemens Healthcare Diagnostics (Llanberis, UK),
urinary iodide based on the Sandell-Kolthoﬀ
reaction.
Surgery. Compartment-oriented microdissection with
systematic removal of lymphatic and fatty tissue was
performed under general anesthesia (24,25). When the
compartment had already been extensively dissected,
recurrent tumor was resected without systematic com-
partment dissection. Neural monitoring was underta-
ken for all relevant nerves including the recurrent
laryngeal, vagus, accessory, phrenic, and hypoglossal
nerves (26,27).
Histopathology. Tissues were ﬁxed in 10% neutral buf-
fered formalin for 2–3 days. Lymph nodes were
bisected along the hilar plane. Five mm sections of sam-
ples embedded in paraﬃn were stained by Hematoxylin
and Eosin (HE), supplemented by immunohistochem-
ical staining for thyroglobulin in selected cases.
Follow-up. All patients were followed with the ima-
ging modalities that had been positive on the ori-
ginal multimodal imaging protocol. A composite
gold standard was based on the best available evi-
dence (histology, cytology, repeat imaging, and/or
clinical follow-up in descending order). Individual
ﬁndings (‘‘lesions’’) were classiﬁed as true/false posi-
tive/negative as reported at the time of the original
study in relation to the composite gold standard
(22). On the patient level, multimodal imaging was
scored as true positive (TP) if at least one TP
lesion was detected, as false positive (FP)/false
negative (FN) in case of at least one FP/FN
lesion in the absence of TP lesions, and otherwise
as true negative (TN). All original image studies
were re-read to detect FN ﬁndings overlooked at
the time of the original report.
Ethics. The project was conducted as a quality surveil-
lance study in full accordance with the guidelines issued
by the institutional review board (IRB) and current
Norwegian legislation, and the IRB exempted the
study from review on 28 February 2014.
Data management, analysis, and statistics. All observations
were registered in MDcake, a client-server database
application developed by our group for the present
study (28,29). Multiple lesions in parenchymatous
organs such as lung or liver were encoded as a single
lesions to avoid biasing lesion-based analysis. Data
were re-aggregated into two SQL views, one for analyz-
ing patients/studies and one for lesions. These provide
the basis for all subsequent analyses. These were con-
ducted with the statistics program ‘‘R’’ (30). For group
comparisons, Wilcoxon rank sum test and Fisher’s
exact test were applied at a signiﬁcance level of 5%
(two-sided).
To evaluate the performance of diagnostic modal-
ities with a continuous (FDG SUV) or ordinal pre-
dictor (I-131 uptake), receiver operating
characteristics (ROC) analysis was performed with
R package pROC. The likelihood of a correct diag-
nosis of a tumor lesion (sensitivity) is plotted against
the likelihood of an incorrectly diagnosed benign
lesion (1 – speciﬁcity) for all possible values of the
predictor. For an ideal method, the ROC curve will
approach the upper left corner of the plot while the
curve will be close to the diagonal for a method
with low predictive power. Ninety-ﬁve-percent conﬁ-
dence intervals (CI) for sensitivity and area under
the curve (AUC) were calculated by bootstrapping
(2000 iterations) (31).
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Results
Patient-based analysis. Multimodal imaging was TP in 32
patients, TN in 16, FP in 2, and FN in 1, yielding a
sensitivity of 97% (95% CI, 94–99) and speciﬁcity of
89% (95% CI, 65–99). Patient characteristics are
summarized in Table 2 and shown in detail in
Supplementary Table 1 (published online only).
Lesion-based analysis. Eighty-six conspicuous lesions were
found in 43 patients (Table 3; see also Supplementary
Table 2, published online only). Fifty-eight lesions were
TP, 19 TN, ﬁve FP, and four FN, yielding a diagnostic
accuracy of 90%, a sensitivity of 94% (95% CI, 84–98),
and a speciﬁcity of 79% (95% CI, 58–93).
Fifty-seven lesions located in the neck or upper
mediastinum accessible to US (in short: ‘‘neck lesions’’)
were analyzed in detail. On ROC analysis, I-131-ima-
ging lacked predictive power with an AUC of 0.51
(95% CI 0.44 – 0.58) for neck lesions and 0.55 (0.46–
0.64) for all lesions (Fig. 1). FDG-PET had high dis-
criminative power with an AUC of 0.80 (0.67 – 0.93)
for neck lesions and 0.68 (0.56 – 0.80) for all lesions.
However, at high sensitivities FDG-PET showed poor
speciﬁcity. The inclusion of CECT in the workup
achieved a high sensitivity of 90 % (76–97) with
improved speciﬁcity of 71 % (44 – 90) compared with
58 % (9 – 88) of FDG-PET alone at the same level of
sensitivity, but without reaching statistical signiﬁcance.
US before PET including optional FNB (preUS) had
limited accuracy of 53 % with a sensitivity of 53 % (36
– 69 %) and a speciﬁcity of 53 % (28 – 77 %) (Figs 2
and 3 for examples). US in the detailed knowledge of
the ﬁndings on PET-CT and SPECT-CT (postUS) out-
performed PET alone and preUS with a speciﬁcity of 94
% (71 – 99) while maintaining sensitivity at 85 % (70 –
94) (p< 0.05 for all comparisons).
To estimate the relative contribution of US with and
without FNB to overall diagnostic performance, we
simulated an imaging workﬂow as outlined in Table 1
with FNB being performed only as the last step of the
protocol. Of the 40 malignant neck lesions, pre-US
without FNB would have correctly diagnosed 18
lesions (45%), and pre-US plus radionuclide imaging
another 18 (45%). Post-US and FNB did not increase
the diagnostic yield over the combination of pre-US
and PET-CT, while four malignant lesions remained
undetected. Of the 17 benign neck lesions, nine (50%)
Table 2. Patients summary.
Parameter All patients, n¼ 51 (%) Disease, n¼ 33 (65%) Disease-free, n¼ 18 (35%)
Female 29 (57%) 18 (53 %) 11 (65 %)
Age (years)* 56 (44–69) 62 (55–75) 52 (38–54) P< 0.002
Age at diagnosis (years) 51 (35–60) 53 (42–65) 36 (30–50) P< 0.002
Haukeland UH 35 (69%) 22 (65%) 13 (77%)
Papillary TC 41 (80%) 25 (76%) 16 (89%)
TNM group> II 32 (67%) 25 (74%) 7 (41%) P< 0.02
Completed TT 51 (100%) 33 (100%) 18 (100%)
Sum I-131 (GBq) 5.6 (3.0–5.6)
[0–30]
5.6 (3.0–5.8)
[0–28]
4.0 (2.2–5.6)
[0.2–30]
Re-operation 13 (26%) 8 (24%) 5 (28%)
Time since TT
(years)
4.2 (2.0–10)
[0.4–30]
4.0 (2.3–9.5)
[0.4–22]
6.4 (1.3–11)
[0.5–30]
hTg (suppressed)
(mg/L)
0.9 (0–12)
[0–903]
6.7 (0.9–37)
[0–903]
0.0 (0.0–0.4)
[0.0–0.9]
P< 0.001
hTg (stimulated)
(mg/L)
8.8 (1.3–40)
[0–7386]
22 (5–85)
[0–7386]
1.6 (0.1–4.6)
[0–19]
P< 0.001
hTg AB 4 (8%) 2 (6%) 2 (12%)
rTSH 45 (88%) 29 (88%) 16 (89%)
Urinary iodide (mg/L) 113 (80–128)
[29–159]
117 (80–128)
[29–159]
103 (85–113)
[74–134]
Follow-up (years) 2.8 (1.7–3.4)
[0.1–4.9]
2.9 (1.7–3.4)
[0.1–4.9]
2.5 (2.1–3.5)
[1.2–4.5]
Patient characteristics according to disease state. Distributions are tabulated as median (interquartile range) [range].
*Age at the time of multimodal imaging (MMI).
Haukeland UH, primary surgery at Haukeland University Hospital; hTg, human thyroglobulin; I-131, cumulative activity of I-131 before MMI; papillary
TC, papillary thyroid cancer; Re-operation, re-operated before MMI; TNM group, TNM stage grouping; TT, thyroidectomy.
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Fig. 1. ROC analysis. For 18F-FDG-PET (FDG) and I-131 scintigraphy (I-131) in neck lesions (neck) or the entire body (all) sensitivity
is plotted against specificity for all possible values of the predictor (standardized uptake value or intensity of I-131 uptake). The
performance of US before PET (Pre-PET) and after PET (Post-PET) as well as the performance of PET-CTare plotted as discrete data
points. Error bars and the gray area around the curve for FDG-PET in the neck indicate 95% confidence intervals.
Table 3. Lesions summary.
Region Malignancy Lesion type* n FDG-pos. I-131-pos. Volume (mL) SUVmax Patients
y (n)
Neck
(n¼ 57)
Malignant Local recurrence 6 6 (100%) 0 0.4
(0.2–0.7)
7.0 (3-12)
[0–49]z
5 22
LN 34 27 (82%) 4 (12%) 21
Benign LN 17 6 (35%) 0 0.4
(0.2–0.9)
1.9 (0-4)
[0–11]z
12 12
Body
(n¼ 29)
Malignant Mediastinum LN 3 2 1 1.3
(0.2–3.5)
2.8 (1-6)
[0–20]
3 15
Lung metastases 9 4 2 9
Bone metastases 9 2 8 3
Other metastases 1 1 0 1
Benign Thymus 4 4 3 3.4
(0.9–7.3)
5.0 (3-6)
[1–7]
2 5
Other 3 1 0 3
Lesion characteristics according to anatomical region: type of lesion, number of lesions (n), FDG uptake, I-131 uptake, lesion volume in mL (median,
interquartile range), SUVmax (median, interquartile range, [range]).
*Lymph node metastases (LN) in neck and upper mediastinum accessible to cervical US (Neck) and mediastinum, distant metastases.
yNumber of patients affected.
zP< 0.001 (Wilcoxon rank test).
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were TN on pre-US and PET-CT while eight (44%)
were FDG-positive. Three (17%) required post-US
and another three (17%) FNB to establish the correct
diagnosis (sparing three patients for unnecessary com-
partment resections for benign disease) while two
remained FP, one of them with a FP FNB.
Outcomes. Multimodal imaging correctly changed the
original therapy assignment in 15 out of 51 patients
(30%) (Table 4). Twenty-four patients underwent sur-
gery, eight in the central compartment, 11 in at least
one lateral compartment, four in the upper mediastinum
(three necessitating sternotomy), and four for distant
metastases (two lung, one adrenal, one hip). Patients
were followed for a median 2.5 years. Two patients
died unrelated to thyroid cancer. Seven patients had pro-
gressive disease, seven patients had stable disease, all in
the group with TP imaging. No recurrences occurred in
the 15 MMI negative patients with exception of patient
20 (Fig. 4). All other patients are in complete remission.
Discussion
High-resolution US is the mainstay of the assessment of
thyroid cancer both for initial evaluation and for
follow-up (10–12,15,16). US may help avoid repeat sur-
gery in up to 40% of patients when compared with
physical examination alone (32,33).
The incremental value of US over other imaging
modalities is more diﬃcult to ascertain. To our
Fig. 2. A 59-year-old patient with unclear rise of hTg. Previous imaging including repeated ultrasound of the neck was negative. 18F-
FDG-PET-CT revealed a paralaryngeal recurrence: Whole-body PET (a), coronal PET slice (b), contrast-enhanced CT (c), and fusion
image (d). I-131-SPECT-CT showed no corresponding uptake (e–g). US after PET revealed an hypoechoic soft tissue lesion (h). US-
guided FNB showed abnormal epithelial cells (i). The patient was treated by endotracheal laser ablation.
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knowledge, our series is the ﬁrst to systematically evalu-
ate the performance of US before and after multimodal
sectional imaging – I-131 SPECT-CT and 18F-FDG
PET-CT – by the same observer in the same cohort
of patients with known or suspected recurrent DTC.
In our prospective analysis of 51 consecutive patients,
US with optional FNB before radionuclide imaging
identiﬁed only 53% of all cancer lesions in the neck,
while US after multimodal imaging had a signiﬁcantly
higher lesion based sensitivity of 85% (P< 0.05). US
after multimodal imaging had the highest speciﬁcity
of 94% versus 53% for US alone and 80% for
Fig. 3. A 54-year-old patient with cytologically confirmed index lesion. Routine US September 2009 revealed a hypoechoic lymph
node behind the left clavicle (a). Cytology showed abnormal epithelium – papillary thyroid cancer (b). As expected, PET-CT showed
FDG uptake (SUVmax 6.4) in the index lesion (panels g, h). In addition it revealed a right-sided paratracheal recurrence (SUVmax 7.0)
that was not visible on US (e, f) and a cystic lymph node metastasis behind the right angle of the jaw (SUV 5.0) that had been
overlooked on initial US. The patient was re-operated with a revision of the cranial right lateral neck (K2/II), the right-sided central
compartment (K1b/IV), and the caudal left lateral neck (K3/V) with preservation of recurrent laryngeal nerve function. All lesions were
histologically confirmed.
Table 4. Therapeutic consequence of multimodal imaging.
Therapy post multimodal imaging incl. post-US
Therapy pre Follow-up* I-131y Surgeryz Extended surgery§ Palliative treatment** 
Follow-up* 20 1 3 4 2 30
I-131y 3 3
Surgeryz 1 7 3 11
Extended surgery§ 1 3 4
Palliative treatment** 0
 22 4 10 10 2 48
*Continuation of follow-up.
yRadioiodine therapy.
zSurgery in a single cervical compartment.
§Extended surgery (at least one more cervical compartment than originally planned).
**Palliative treatment¼ external beam radiotherapy and endotracheal laser ablation in one patient each.
The line of identity is emphasized in gray. The 13 patients in the white area to the upper right received more aggressive therapy than planned. Two
patients in the white area to the lower left were downstaged and assigned to follow-up without surgery. The two patients with FP imaging (Follow-
up!Surgery) and the one patient with FN imaging (Follow-up!Follow-up) are not listed.
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18F-FDG-PET alone (P< 0.05). High speciﬁcity is
necessary to avoid futile surgery based on FP ﬁndings.
In a simulated workﬂow assuming FNB as the last step
in the diagnostic algorithm, pre-US and radionuclide
imaging together would have identiﬁed 90% of all
malignant neck lesions with no further increase in sen-
sitivity by post-US and FNB. Post-US and FNB were,
however, vital for the correct diagnosis of benign
lesions with non-malignant reactive or inﬂammatory
FDG uptake, increasing speciﬁcity from 50% for
PET-CT alone to 90% for PET-CTþ post-USþFNB.
We therefore strongly recommend post-US with
optional FNB for the evaluation of all FDG-positive
neck lesions in patients with thyroid cancer, at least
when surgery is considered. For the evaluation of clin-
ically suspicious neck lesions and for routine follow-up,
US supplanted by FNB up front is the most eﬃcient
ﬁrst-line imaging modality: FNB of an index lesion will
quickly establish or refute the indication for further
imaging or therapeutic intervention, while it will also
establish the correct diagnosis of malignancy in lesions
that would be missed by PET-CT alone.
The main imaging modality chosen for the evalu-
ation of US was 18F-FDG-PET as it is the most
sensitive imaging method for the evaluation of recur-
rent DTC. In a systematic meta-analysis performed
by Dong et al. in 2009, FDG-PET had a pooled
lesion-based sensitivity of 91.6% and a patient-based
sensitivity of 88.5% in patients with elevated hTg and
negative I-131 scintigraphy (14). Speciﬁcity of FDG-
PET was, however, limited to 77.5% (lesion-based)
and 84.7% (patient-based), which compares well with
our own results.
We were disappointed by the performance of cer-
vical US when performed alone (pre-US). The most
detailed head-to-head comparison of US and FDG-
PET was performed by Seo et al. (34). In 20 thyroid
cancer patients (19 PTC, 1 MTC) with cytologically
proven recurrence, US, CECT, and PET-CT were com-
pared with histology in each of 110 nodal levels that
were surgically explored. Sensitivity and speciﬁcity for
US was 69.2% and 89.7% for CECT 63.5% and
94.8%, and for PET-CT 53.8% and 79.3%. These ﬁnd-
ings based on histology as the sole gold standard are
largely in agreement with ours. The sensitivity of US is
likely overestimated, since only patients with positive
FNB of at least one cervical lesion were included.
Only a few studies allow estimates of the sensitivity
of US when performed independently of 18F-FDG-
PET. In a series with 49 patients with DTC and positive
serum hTg, only one out of six local recurrences was
found on pre-PET US while ﬁve were seen on CECT
and PET. All were conﬁrmed by hTg in US-guided
FNB after PET (35). In a recent multicenter series
Fig. 4. FN multimodal imaging in a 49-year-old patient. Routine US had detected a suspicious lymph node behind the right angle of the
jaw with microcalcifications (a). 18F-FDG-PET (b, c) and I-131-SPECT-CT (not shown) showed no tracer uptake. US-guided FNB was
FN. On repeat imaging with new US machine (d), the lymph node showed focal hyperperfusion not observed in the surrounding
nodes. New cytology was positive (e) with a human thyroglobulin in the washout from the needle of 855 ng/L. FDG-PET was still
negative (not shown). Re-operation revealed one metastasis in 21 lymph nodes.
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with 327 patients, per-patient sensitivity and speciﬁcity
was 37% and 94% for US, and 92% and 95% for PET/
CT (36). In a single-center study in 423 patients, 16 out
of 90 recurrent lesions were missed on US, but diag-
nosed with FDG-PET-CT (23).
Our observation that cervical US misses cancerous
lesions is further conﬁrmed by studies that only
included patients with negative conventional imaging
including US. In a series of 34 patients with 30 tumor
lesions in the neck, new US detected 18 (including three
that were FDG-negative), CECT 14, and FDG-PET 27
(37). In another recent prospective series, FDG-PET/
CT had a per-patient sensitivity of 87%, and a speciﬁ-
city of only 77% implying that the majority of the
lesions had been overlooked at baseline US (38).
Similar observations were made by Pomerri et al. (39)
and Freudenberg et al. (40).
There are limitations connected to our study.
Ideally, the standard for evaluating a diagnostic
method should be completely independent of the
method under study (41). A correct estimate of the spe-
ciﬁcity of a diagnostic method and its positive predict-
ive value requires also a suﬃcient number of negative
observations (42). If histological specimens were taken
as sole gold standard, the last condition can only be met
if prophylactic lymph node dissection is performed even
in the absence of disease demonstrable by imaging. In a
series of 560 patients by Ito, US had a per patient sen-
sitivity of 27.2% and a speciﬁcity of 96.5% compared
with histological specimens (43). Preliminary results
from our own series and a smaller recent study (44)
conﬁrm that imaging underestimates the number of
malignant lesions compared with histological prepar-
ations. Results from Ito’s series (43,45) imply that
micrometastases in cervical lymph nodes do not have
the same prognostic relevance as macrometastases that
are detected clinically or by cervical US. Thus measur-
ing the performance of cervical US against histology
may not lead to appropriate conclusions for the clinical
management of patients with DTC.
Misdiagnoses in two patients in our series could have
probably been avoided, if we had analyzed hTg from
the washout of the US-guided FNB as we did from
February 2011. The thymic lesions were unfortunately
inaccessible to percutaneous biopsy.
The proportion of patients with iodine-avid lesions
in our cohort was lower than in a recent German series,
in which 78 out of 327 patients (24 %) had TP ﬁndings
on I-131 scintigraphy (37). In two recent series from
France and Italy, only one out of 34 hTg-positive
patients had therapeutically relevant I-131 uptake
(37), and only one of 22 patients had therapeutically
relevant uptake in a pulmonary metastasis (46).
Measurements of urinary iodine excretion in our
patients exclude iodine contamination as a cause for
our observation. As a consequence of this study, we
have altered our protocol from combined imaging/ther-
apy with 3 GBq I-131 to imaging with I-123, a pure
gamma emitter, in order to reduce radiation exposure
particularly to the salivary glands (47).
In conclusion, in patients evaluated for recurrent
DTC after previous ablative therapy US performed
independent of other imaging modalities misses about
half of cancer lesions in the neck while 18F-FDG-PET
is sensitive but lacks speciﬁcity. US performed in cor-
relation with 18F-FDG-PET-CT maintained the sensi-
tivity of FDG-PET, but increased speciﬁcity by
eliminating false positive diagnoses due non-malignant
FDG uptake in cervical lesions.
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Supplementary material is available online at acr.sagepub.
com/supplemental.
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